Objective. To create a literature review between 2011 and June 1, 2015, on advances in otitis media (OM) epidemiology and diagnosis (including relevant audiology studies). Data Sources. Electronic search engines (PubMed, EMBASE, and Cochrane Library) with a predefined search strategy.
Methods
The main search strategy was otitis media (exploded) linked with subheadings «epidemiology» or «genetics» or otitis media (exploded) AND (risk or logistic models or risk assessment or risk factors or incidence or prevalence). PubMed was searched with a predetermined string: ( 
Inclusion Criteria
We included systematic reviews, individual randomized controlled trials (RCT), and studies of epidemiology, diagnosis, guidelines, and quality of life published from 2011. Studies with insufficient description of the methods to allow replication, without ethical approvement, or with \20 participants were excluded.
Data and Quality and Risk-of-Bias Assessment
We extracted data concerning methods, the population under study, diagnostic tests, outcome, and relevant results. We considered relevant risk of bias, sample selection and assessed methods of randomization (or control for confounding), blinding, outcome, follow-up, and trial registration when available. For observational diagnostic studies, we considered suitability of study population, independence of assessment, reliability of gold standard, and follow-up.
Discussion

OM Worldwide and in High-Risk Populations
OM is a worldwide problem. Many recent studies and some reviews from developing countries show large OM differences among areas and ethnic groups. Mahadevan et al (2012) found that reported OM prevalence in school-age children ranged from 3.3% in Thailand to 12.2% in the Philippines and was highest in Australian Aboriginal children (42%). Chronic suppurative OM (CSOM) prevalence was 5.4% in Indonesia (all ages), 15% in Australian Aboriginal children, and between 2% and 4% in Thailand, Philippines, Malaysia, and Vietnam. 1 Monasta et al (2012) performed a systematic review of 114 prevalence studies and found, based on a hypothetical model, an acute OM (AOM) incidence rate of 11% (709 million cases each year, 51% in children \5 years old). 2 Corresponding CSOM incidence rate was 5& (31 million cases), of whom 23% were children \5 years old. The authors estimated that 21,000 people die due to OM complications annually. Bardach et al (2011) reported in a systematic review and meta-analysis of the annual AOM incidence in children \5 years old from Latin America and the Caribbean ranged from 1171 to 36,000 episodes per 100,000 children. 3 Findings from new OM prevalence studies. Several new population-based prevalence and incidence studies have been published since the last ISOM meeting in 2011 ( Table  1) . The combined sample size of these populations is 29,343 children \18 years old. It is a concern that CSOM (variably defined) remains a global problem. The World Health Organization (WHO) cutoff for a public health emergency has been set to CSOM rates .4%.
Findings from new OM and acute mastoiditis incidence studies.
The new incidence studies rely on reports of health care facility activity and on population-based surveys. Todberg et al (2014) examined a population-based Danish National Birth Cohort to determine the burden of OM (by parental recall at 6 months, 18 months, and 7 years). 14 The cumulative incidence at 7 years was 60%. The rate of 41 OM episodes by age 7 years was higher among children whose first episode was before 6 months (64% vs 39%). Pritchett et al (2012) used HCUP-KID (Healthcare Cost and Utilization Project-Kids Inpatient Database) to determine hospital admission rates for acute mastoiditis (AM) and found no significant AM incidence increase from 1997 to 2006 (P = .37). 15 Anthonsen et al (2013) reported unchanged AM incidence and a low complication rate in Denmark with low use of antibiotics. 16 AM incidence estimates from Italy and Sweden have also been published since 2011 (see Table 2 ).
OM-Related HL
The global epidemiology of OM-related HL is not uniform, as the subtypes of OM vary between the developed and developing parts of the world and among certain indigenous populations. Comparing OM-related HL among studies (see Table 3 ) is complicated by the variation in HL definitions, which may contribute up to a 20-fold difference in prevalence. 23 The global prevalence of OM-related HL (WHO definition) has been estimated as 31 per 10,000, corresponding to 20 million cases. 2 The identified prevalences were lower than previous WHO estimates and should be confirmed by epidemiologic studies.
All studies in Table 3 are population based unless stated otherwise. In a cohort study, Yiengprugsawan et al (2013) found OM-related HL reported by the parents in 2.8% to 3.1% of non-Indigenous Australian children and in 4.0% to 7.5% of Indigenous children. 26 Two large cohort studies showed that childhood ear infection is associated with an increased risk of HL later in life. 5, 27 found a 91% absolute risk of getting permanent HL after CSOM in childhood. 23 Lok et al (2012) investigated risk factors for OM-related HL and found them to be similar to known risk factors for OM. 28 Taipale et al (2011) identified HIV as an important risk factor for OM-related HL in a primary health care Otoscopic findings included ''retraction, hyper-vascularisation of the membrane, air/fluid levels behind the membrane, air bubbles behind the membrane or limitations of motion in the membrane detected by otoscope.'' c Yamamah provided prevalence rates by ears, not by children.
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case-control study, where 26% of HIV-positive children had HL that was associated with OM in 19 of 30 ears (63%). 29 Borges et al (2013) found that children with previous otitis media with effusion (OME) had impaired auditory skills at the 8 to 12 years of age. 30 Hall et al (2014) demonstrated, in a cohort study, that cumulative exposure to OME and HL was associated with lower scores in IQ tests later in life. 31 Children from homes with low levels of cognitive stimulus were more susceptible to the negative effects of OME and HL.
News in OM Diagnostics
New diagnostic studies included interventions, diagnostic accuracy and agreement, and severity studies. No systematic reviews of intervention studies or RCTs were found.
Diagnostic accuracy studies. A systematic review in the updated US AOM guidelines described typical clinical features and highlighted tympanic membrane bulging. 32 Gyo et al (2013) studied preoperative assessment of computed tomography (CT) 2-dimensional reformation and 3dimensional volume rendering in CSOM. 38 The former method had a sensitivity of 86% to 100% and a specificity of 86% to 100%; the latter had a sensitivity 91% to 100% and a specificity of 87% to 100%. Tatlipinar et al (2012) also assessed the value of preoperative CT in chronic OM. 39 CT-suspected cholesteatoma was confirmed in only 62%. Shaikh et al (2012) tested their algorithm (nonindependent reference standard = clinical diagnosis) in 783 children to diagnose AOM (sensitivity 96%, specificity 100%) and OME (sensitivity 98%, specificity 99%). 40 Diagnostic agreement studies. No systematic reviews have been reported. Lundberg et al (2014) described substantial intra-and interrater agreement of remote video otoscopy (weighted kappa ranges: 0.85-0.88 and 0.69-0.72, respectively). 41 Shaikh et al (2011) described fair interrater agreement of 93% to 96% of bulging of the tympanic membrane for AOM and 0% to 3% for OME based on images of individual features of OM. 42 Erkkola-Anttinen et al (2014) found substantial agreement for tympanometry by parents and physicians (kappa value, 0.77). 43 Heidemann et al (2013) assessed repeatability of the OM6 translated into Danish and found high intraclass correlation coefficients between 0.77 and 0.88 for reproducibility. 44 Vlastarakos et al (2012) assessed agreement between preoperative CT and 10 specific middle ear findings at operation and found a range of sensitivity (0%-94%) and specificity (0%-100%). 45 McCoul et al (2012) found acceptable repeatability (r = 0.78) of the Eustachian Tube Dysfunction Questionnaire. 46 Van Dongen et al (2012) reported substantial agreement between parent-reported otorrhea and otoscopy/otomicroscopy by physicians with (positive predictive value, 90%; negative predictive value, 85%). 47 Assessment of severity studies. There have been no systematic reviews. Casey et al (2011) described a strong association (positive predictive value, 91%; negative predictive value, 97%) between AOM 10-point score and clinical failure (reference standard not independent). 48 
Pre-and Postnatal Risk Factors and Comorbidity
Prenatal risk factor studies are scarce. Myiashita et al (2011) prospectively studied 364 mothers/infants in Japan and assessed the association between dioxin levels in maternal blood and risk of infant OM before 18 months of age. 49 High levels of polychlorinated dibenzofuran and 2,3,4,7,8pentachlorodibenzofuran were significantly associated with increased risk of questionnaire-based OM (odds ratio = 2.5, 95% confidence interval [95% CI] = 1.1-5.9), especially among male infants (odds ratio = 5.3, 95% CI = 1.5-19). The effects of prenatal exposure to dioxins may be caused by immunosuppression. A birth cohort study examining cord blood levels of persistent organochlorides from children in Greenland did not show any association with later OM episodes. 50 Several prevalence and incidence studies include risk factor associations. 9, 54 upper respiratory tract infection (URTI), 4, 9, 54 allergy, 9, 53, 54, 59 daycare attendance, 4, 14, 53 and smoke exposure 4, 14, 50, 54, 57 are still reported as risk factors. AH may, at least in part, act by obstructing the eustachian tube (ET), becoming a bacterial biofilm leading to infection. Smoke exposure may affect mucociliary clearance, leading to blockage of the ET, while allergy/URTIs may cause nasal congestion, ET dysfunction, or AH. In AH children, male sex, congenital diseases, and school attendance were identified as risk factors for OME. 66 Pettigrew et al (2011) showed a synergistic effect of bacterial AOM when coinfection occurs with respiratory viruses. 56 Baseline trends before pneumococcal vaccination in The Netherlands were evaluated over a 10-year period and showed that consultation rates for OM were unchanged, while lower respiratory tract infections increased by 42% and URTIs declined by 5%. 67 In a prospective cohort study, middle ear effusion in children with URTIs were analyzed for viral load/cytokine production. 68 Presence of bacteria, but not viruses, was associated with an increased inflammatory response in the middle ear.
Weight, 60,61 gastroesophageal reflux disease (GERD), 65 and vitamin D 63 appear to be related to OM. OM risk factors overlap with obesity, suggesting a potential confounder. Cytokines involved in innate immunity are decreased in obese individuals and may increase the susceptibility of the host to infection. Obesity has also been linked to increased adiposity tissue surrounding the ET and risk of GERD. 69 Two cross-sectional studies support the association of OM, and in an observational study, neither OM history nor diet was associated with an increased body mass index. 60, 61, 70 In a systematic review, the prevalence of GERD in children with chronic OME was 48.4% and in recurrent AOM (rAOM), 62.9%. 71 Mean pepsin/pepsinogen presence and enzymatic activity in OM were 85.3% and 34.2%, respectively. However, the review noted that antireflux treatment in 2 RCTs failed to prove benefit. Vitamin D is an evolving postnatal risk factor, as it may affect production of antimicrobial peptides and it is involved in innate immunity. One well-designed RCT has shown a benefit in decreasing OM with supplementation. 63 Probiotics 64,72 and zinc 73 continue to show little benefit in reducing OM. In regard to zinc, a 2014 Cochrane review summarized 2 RCTs involving healthy children living in low-income communities, which found no differences in OM incidence with zinc supplementation; a third trial showed a lower incidence rate of OM in the treatment arm. 74 
OM Genetics
Genetic OM susceptibility could lead to identification of high-risk individuals and new preventive and therapeutic strategies. An overview of the previous 4 years of heritability studies of OM, including studies identifying new genetic regions influencing the risk of OM, are shown in Table 11 .
Heritability. Heritability studies quantify the relative importance of genetic and environmental factors in disease susceptibility. A recent study confirmed the substantial genetic component to OM susceptibility reported in previous studies. 74 Linkage analyses. When a substantial genetic component is confirmed for a trait, gene-finding studies are needed to identify the regions in the genome affecting disease susceptibility. Linkage studies 75, 76 identify larger regions of the Abbreviations: AOM, acute otitis media; GERD, gastroesophageal reflux disease; OM, otitis media; OME, otitis media with effusion; RCT, randomized controlled trial. genome where disease susceptibility loci are located. Data from sets of pedigrees with at least 2 affected individuals are used to test if the marker is inherited with the disease within the family. The logarithm-of-odds score is used to indicate the strength of the association, and a score 3 is by convention considered statistically significant.
Candidate gene studies. In candidate gene association studies, [77] [78] [79] [80] [81] allele frequencies among affected individuals are compared with the allele frequencies in healthy controls. The innate immune system is fully functioning at birth, and it is important after the maternal immunity has waned and before the adaptive immunity has developed. Since the peak prevalence of OM is in early life, the genes regulating the different components of the innate immune system have been candidate genes in OM molecular genetic studies.
Genomewide association studies. In genomewide association studies 82, 83 (GWASs), no a priori assumptions are required about loci contributing to disease susceptibility. Singlenucleotide polymorphisms along the genome are used as markers to identify genetic regions associated with disease susceptibility. Results from GWASs are presented in Table 11 .
Microbiological Epidemiology
Changes in AOM incidence have been reported since the start of the pneumococcal conjugate vaccine (PCV) era, contributing to the picture of AOM incidence and the association to microbial epidemiology in the post-PCV era. An update to a Cochrane meta-analysis on the effect of PCVs in preventing AOM in children up to 12 years of age was published in 2014. 84 Eleven publications of 9 RCTs of 7-to 11-valent PCVs with different carrier proteins were included. All were studies published before 2011. Five trials included infants, and 4 trials comprised children aged 1 to 7 years who were healthy or had a history of URTI, including AOM. The authors concluded that, based on the current evidence of the 9 trials, the licensed PCV7 conjugated to CRM197 had a modest beneficial effect on reduction in allcause AOM episodes when given to healthy infants but that the PCV7 significantly reduced pneumococcal AOM episodes. Administering PCV7 after early infancy in high-risk infants and older children with a history of AOM does not positively affect the occurrence of AOM episodes. Hau et al (2014) summarized the impact of PCVs on microbial epidemiology and clinical outcomes of AOM, including 6 RCTs, 9 postlicensure observational or cohort studies, and 5 studies on the effects of PCV on the microbiology of AOM episodes. 85 The studies varied in vaccines tested, study design, inclusion criteria, and outcome measures. The postlicensure studies observed greater efficacy of the PCVs on the incidence of AOM, rAOM persistence, or treatment failure as compared with the prelicensure RCTs. Prior to PCV adoption, Streptococcus pneumoniae was the most common cause of AOM. In the early years following PCV7 implementation, there was a reduction of vaccine serotype S pneumoniae in AOM, and a proportional increase in nontypeable Haemophilus influenzae and nonvaccine S pneumoniae serotypes was found. Six to 8 years following the introduction of PCV7, an increase in S pneumoniae AOM due to nonvaccine serotypes, primarily serotype 19A, has been documented such that S pneumoniae and nontypeable Haemophilus influenzae accounted for equal proportions of AOM episodes. In 2012, Taylor et al published a systematic review of the impact of PCVs on all-cause AOM. 83 Eighteen publications (15 studies) met inclusion criteria, comprising 7 clinical trials and 8 observational database studies. Of the clinical trials studying PCV7, efficacy against all-cause AOM episodes was estimated at 0% to 9% in the RCTs and 17% to 23% in non-RCTs. Observational database studies reported an average decrease of 19% in AOM visit rates. The authors concluded that the vaccine provides some protection against OM but that other factors have contributed to the recent decline in OM incidence and that the studies with high-risk, potentially otitisprone children generated a lower immune response to the vaccine and experienced a lower vaccine efficacy rate. Three database trials in 3 countries demonstrated a positive effect of PCVs on AOM episodes. Marom et al (2014) analyzed an insurance claims database of a US nationwide health care plan and showed a decreased trend in OMrelated health care use in children \6 years old. 87 Magnus et al (2012) studied children in the Norwegian Mother and Child Cohort Study and showed a decline of motherreported AOM episodes in 12-to 18-month-olds and 18-to 36-month-olds of 14% and 8%, respectively. 88 Using a national primary care database, Lau et al (2015) performed an observational cohort study to investigate the trends in AOM incidence and associated antibiotic utilization in children \10 years old from 2002 to 2012 in the United Kingdom. 89 The authors found that the introduction of PCV7 was associated with a 22% reduction in AOM in children \10 years old and an additional 19% reduction following PCV13 introduction. One study reported AOM microbiology data following the transition to PCV13. Ben-Shimol et al (2014) observed a rapid decline in the incidence of AOM among children \2 years old in Israel and a decrease in serotypes 1, 3, 5, 7F, and 19A isolated from mouse embryonic fibroblast cultures from 1.2 to 0.3 per 1000 persons. 90 Guidelines Guidelines for AOM. Guidelines aim to improve health care and outcomes. In AOM guidelines, the reduction in antibiotic overuse to decrease antibiotic resistance is an important issue. This may lead to an increase in complications as AM. However, studies from Scandinavia and the United States have not demonstrated such a negative effect 16, [18] [19] [20] (see Table 3 ). Concerning guidelines for referral for rAOM in children \2 years old, a Dutch study found that 57% of the referrals were not in accordance with the guideline of .3 episodes of AOM in 6 months or .4 episodes in 12 months. 91 Pichichiro et al (2013) compared 3 groups of children who were followed from the age of 6 months until 3 years: (1) the intervention group based on stringent AOM criteria and treated with amoxicillin/clavulate and tympanocentesis, (2) strict-diagnosed controls without tympanocentesis, and (3) community controls treated according to the American Academy of Pediatrics guideline of 2004. 92 In total, 5.9% of children in group 1 became otitis prone and 2.9% received tympanostomy tubes (TTs), compared with 14.4% and 6.3% in group 2 and 27.3% and 14.8% in group 3 (P \ .0001). Only 10% of the children in the intervention group benefited from the need to change antibiotic therapy, indicating that tympanocentesis alone may have an independent effect. Preventing with vaccination or more effective treatment of a first episode of AOM might prevent recurrence. These findings are not in accordance with a Cochrane review of antibiotics for AOM that did not show any difference in rAOM between antibiotic treatment and placebo (risk ratio = 0.93, 95% CI = 0.79-1.10). 93 Fleming-Dutra et al (2014) found, in multivariable analysis, that black (vs nonblack) race was negatively associated with broadspectrum antibiotic prescribing (adjusted odds ratio = 0.59, 95% CI = 0.40-0.86) and thus more often treated according to the guideline. 94 The main changes in the updated American Academy of Pediatrics / American Academy of Family Physicians 2004 AOM guideline are increased accuracy in diagnosing AOM and observation with close followup for unilateral AOM in children 6 to 23 months of age with mild otalgia for \48 hours, temperature \39°C, just as in older children. 95 This is in contrast to Hoberman et al (2013) , who found no differences in outcome with antibiotic treatment compared with placebo in children presenting with unilateral or bilateral nonsevere AOM (number needed to treat = 4) in 2 trials of children \2 years of age, 96, 97 therefore recommending antibiotics for all children \2 years of age.
Guidelines for TTs in children. Several new guidelines on TT placement have been published-among these, the American clinical practice guideline on TT. 98 Kao et al (2014) investigated adherence to the 2002 American Academy of Pediatrics guidelines for follow-up of TT patients. 99 In 74%, resolution of symptoms were not confirmed. Noncompliance to scheduled follow-up was associated with noncompliance of the first postoperative visit, the distance between home and the clinic, patient age (younger children were more compliant), and insurance type. High percentage of noncompliance may give otolaryngologists a biased impression of their results of TT placements. Daniel et al (2014) found no significant changes with respect to having 2 audiograms 3 months apart (57.8% vs 54.8%), OME persisting at least 3 months (94.8% vs 92.5%), fulfilment of the 25-dB audiometric criteria (68.2 vs 61.0%), or clinical practice after TT insertion for OME before and after the introduction of the National Institute for Clinical Excellence guidelines in 2008. 100 A significant number had surgery due to the invoking of exceptional criteria, suggesting that clinicians were personalizing their treatment to each child.
Quality of Life
Health-related quality of life (HRQoL) in children with common pediatric otolaryngologic disorders is being evaluated in an increasing number of studies. 101 AOM/OME. Heidemann et al (2013) performed a thorough translation of the OM-6 questionnaire into Danish and assessed psychometric properties in 435 Danish children with AOM or OME. 44 Certain items were closely correlated, which may influence structural validity and internal consistency. Ryborg et al (2014) assessed HRQoL in a cohort of children presenting new ear problems at their family physician, comparing HRQoL at baseline with that at 13 months. HRQoL significantly improved after 13 months in children with OM but less in the subgroup of children with sleep problems. 102 Kulpeng et al (2013) aimed to quantify the variation of different HRQoL questionnaires used in young patients. In a hospital-based cross-sectional survey in 7 tertiary hospitals in Thailand, HRQoL was assessed in a total of 173 patients, of whom 18 had AOM. 103 A high correlation among the instruments was found except from the EuroQol visual analog scale, which exhibited low correlation with the others.
CSOM. An overview of available HRQoL questionnaires for patients with deafness has been published, in particular for CSOM. 104 Baumann et al (2011) assessed HRQoL in 90 patients with CSOM and found audiometry correlated with the hearing function subscale from the COM Outcome Test 15. 105 Phillips et al (2014) developed a new HRQoL questionnaire (COMQ-12) for CSOM patients. Psychometric analyses were performed with a heterogenous sample of 50 patients. 106 Sufficient consistency and validity information were obtained to justify clinical use of the COMQ-12. Bakir et al (2013) reported on HRQoL in 55 CSOM patients and 55 matched controls who filled out the Symptom Check List 90-Revised Form and the Short Form-36 and found that CSOM patients had significantly lower HRQoL in several parameters. 107 Some of the most important epidemiologic achievements from 2011 to 2015 are highlighted in Tables 12-15 . Still no generally accepted golden standard for the diagnosis of AOM Tympanometry is yet to be replaced as the preferred method to evaluate middle ear status. Tympanometry needs to be supplemented by pneumatic otoscopy for the diagnosis of OM. Video otoscopy is a valuable diagnostic tool. Parents can be trained to perform reliable tympanometry. An algorithm using bulging and opacification of the tympanic membrane correctly classified 99% of ears. The ETDQ-7 looks promising to discriminate eustachian tube dysfunction. A 10-point AOM score sheet is excellent to predict clinical failure. Eosinophilic OM may be a new diagnostic entity.
Abbreviations: AOM, acute otitis media; OM, otitis media. Guidelines for acute OM are well suited to reduce resistance by minimizing the overuse of antibiotics. Tympanocentesis may have an independent effect to antibiotic treatment in recurrent acute OM risk reduction. The discussion remains whether OM symptoms or OM signs should be treated. Implementation of guideline advice is challenging and needs to be targeted. Evidence suggests that physician autonomy plays a significant role when individual OM treatments plans are made, at the expense of guidelines. The OM-6 questionnaire is a valuable tool. New chronic OM questionnaires have been developed. Methodological tools and a priori assumptions have large implications on the validity of study results. Abbreviation: OM, otitis media.
herd effect studies are needed to further elucidate the efficacy of PCVs. Combined effect studies of PCV and influenza vaccines are warranted. Tracking of vaccine impact should be continued. 9. Although several countries have introduced guidelines in OM diagnosis and treatment, high-quality studies such as RCTs are scarce and recommendations often based on weak evidence. Prospective monitoring of guideline impact and adherence is needed. This will require benchmarking abilities, such as hospitalization for AOM. Benchmarks will vary among countries due to differences in treatments. Another benchmark could be whether the usage of antiobiotics is according to guideline recommendations (ie, less use of antibiotics for AOM). Comparison of guideline adherence differences among countries is encouraged. Studies from The Netherlands, the United States, and the United Kingdom suggest lack of adherence to guidelines concerning referral of rAOM patients, follow-up after TT insertion, change in practice according to guidelines, and differences in treatment among races, implying that physicians individualize their treatment. 91,94,99,100 Improvement of guideline introduction into practice is needed. 10. Although OM has been shown to affect quality of life in children and their families, large-scale quality-of-life studies have yet to be performed.
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